Clomipramine HydrochlorideThird Party Manufacturing in India

Clomipramine Hydrochloride works primarily by potently inhibiting the reuptake of serotonin and, to a lesser extent, norepinephrine at the presynaptic neuronal membrane. By blocking serotonin transporters and norepinephrine transporters, it increases the availability of these neurotransmitters in the synaptic cleft, enhancing serotonergic and noradrenergic neurotransmission. Clomipramine has a significantly higher affinity for the serotonin transporter compared with the norepinephrine transporter, which distinguishes it from other tricyclic antidepressants and underpins its particular efficacy in obsessive-compulsive disorder.

With chronic use, clomipramine downregulates cerebral cortical beta-adrenergic receptors and sensitizes postsynaptic serotonergic receptors, contributing to its delayed therapeutic onset. The drug is demethylated in the liver via CYP2D6 and CYP2C19 to its primary active metabolite, desmethylclomipramine, which also inhibits norepinephrine reuptake and contributes to the overall pharmacological effect. Additionally, clomipramine antagonizes histamine H1 receptors, muscarinic acetylcholine receptors, and alpha-1 adrenergic receptors, which accounts for its sedative, anticholinergic, and hypotensive side effect profile respectively.

Clomipramine Hydrochloride is a tricyclic antidepressant primarily indicated for the treatment of obsessive-compulsive disorder and related conditions.

• Obsessive-Compulsive Disorder: The primary FDA-approved indication, where clomipramine reduces the frequency and intensity of obsessions and compulsions.
• Major Depressive Disorder: Effective for depression, particularly when accompanied by obsessive features or anxiety.
• Panic Disorder with or without Agoraphobia: Used off-label for panic symptoms unresponsive to SSRIs.
• Chronic Pain Syndromes: Prescribed for neuropathic pain, tension headache, and diabetic peripheral neuropathy.
• Cataplexy and Narcolepsy: Helps manage cataplexy episodes and associated sleep disturbances.
• Premature Ejaculation: Used off-label for its serotonin reuptake inhibition properties.

Clomipramine Hydrochloride holds a stable position in the Indian psychiatric pharmaceutical market despite competition from SSRIs. It is manufactured in tablet forms (10mg, 25mg, and 50mg) and continues to be prescribed as a second-line agent when SSRIs fail or are poorly tolerated. Its listing on the WHO Model List of Essential Medicines and its cost-effectiveness make it a valuable molecule for PCD franchise operators and third party manufacturers serving the mental health segment. Indian WHO-GMP certified manufacturers supply clomipramine hydrochloride to both domestic and export markets, with particular demand from price-sensitive healthcare systems in Asia and Africa.